First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Qiagen: the story is balanced — Molecular diagnostics consumable growth rates, particularly oncology and infectious disease testing volumes in clinical…
★ Analysts see FY2027 revenue reaching $2.3B — +5.2% growth in a single year.
What Moves the Stock
1Molecular diagnostics consumable growth rates, particularly oncology and infectious disease testing volumes in clinical labs
2Pharma/biotech R&D spending trends affecting Life Sciences segment demand for sample prep kits and NGS workflow products
3New product launch momentum for QuantiFERON-TB, QIAstat-Dx syndromic testing, and liquid biopsy assays with associated reimbursement approvals
4Instrument placements (QIAsymphony, QIAcube Connect) driving future consumable pull-through at 3-5x instrument revenue over lifecycle
5Currency headwinds given ~40% USD revenue exposure and euro-based cost structure
6Molecular Diagnostics (~35-40% of revenue): Clinical testing consumables and instruments for infectious disease, oncology, and genetic testing in hospital/reference labs
7Life Sciences (~35-40% of revenue): Sample preparation kits and reagents for pharma/biotech R&D and academic research applications
8Applied Testing (~20-25% of revenue): Forensics, veterinary diagnostics, and food safety testing solutions
value - Stock trades at 15x EBITDA versus 20-25x for high-growth diagnostics peers…
Rising rates create modest headwinds through two channels: (1) Biotech funding environment tightens…
Watch on earnings: US and EU biotech/pharma R&D spending growth rates as leading indicator for Life Sciences segment demand, Clinical laboratory testing volumes and reimbursement rate changes for molecular diagnostics procedures, Instrument placement counts by platform (QIAsymphony, QIAcube) and associated consumable pull-through ratios.
One Sentence Summary:
Qiagen: the story is balanced — molecular diagnostics consumable growth rates, particularly oncology and infectious disease testing volumes in clinical labs.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.